Tesla Seeks Approval to Make Batteries at New Texas Plant

Tesla  (TSLA) – Get Report won’t only be assembling the Cybertruck at its new Gigafactory in Austin, Texas, when it turns on the switch next year: The company also plans to mass-produce batteries.

Tesla has filed documents with the Texas Commission on Environmental Quality seeking permission to operate a “cell-manufacturing unit” at what it calls Tesla Giga Austin.

According to a 188-page air-quality permit application filed sometime between July and last month, Tesla is proposing “to operate a cell-manufacturing unit to produce the battery packs that are installed in the vehicle.”

GHD Services, which reportedly submitted the registration on Tesla’s behalf, said in the application that six nitrogen-blanketed tanks, each with a volume of 20,000 liters, will be necessary to manufacture the cells, according to reports.

The environmental permit application was first reported by the Austin Business Journal.

At Tesla’s “Battery Day” event last month. CEO Elon Musk

Read More

Tesla Seeks Approval for Battery-Cell Output at New Texas Plant

(Bloomberg) — Tesla Inc.’s new factory in Austin, Texas, won’t build only the Cybertruck: State filings suggest the company also plans to make batteries on site as part of an ambitious strategy to further integrate its supply chain.



a hand holding a remote control: Martin Sukup, an electrical engineer for Tesla Motors Inc., demonstrates the charging procedure on an S sedan before the grand opening of the Tesla Supercharger station in Lebec, California, U.S., on Friday, Oct. 19, 2012. T


© Bloomberg
Martin Sukup, an electrical engineer for Tesla Motors Inc., demonstrates the charging procedure on an S sedan before the grand opening of the Tesla Supercharger station in Lebec, California, U.S., on Friday, Oct. 19, 2012. T

“The facility is proposing to operate a cell-manufacturing unit to produce the battery packs that are installed in the vehicle,” says an 188-page air-quality permit application filed with the Texas Commission on Environmental Quality. The documents Bloomberg reviewed were filed between July and September.

Loading...

Load Error

Chief Executive Officer Elon Musk announced during the electric-car manufacturer’s quarterly earnings call in July that Tesla had chosen Austin as the site of its next plant. In

Read More

Japan’s Sony and Kioxia seeking U.S. approval to supply to Huawei – Nikkei

FILE PHOTO: A Huawei company logo is pictured at the Shenzhen International Airport in Shenzhen, Guangdong province, China, July 22, 2019. REUTERS/Aly Song/File Photo

TOKYO (Reuters) – Japan’s Sony Corp and memory chipmaker Kioxia Holdings Corp have applied for U.S. approval to continue supplying Huawei Technologies Co Ltd, Nikkei reported on Sunday.

If confirmed, the move follows other tech companies such as Intel Corp that recently received licences from U.S. authorities.

With U.S.-China ties at their worst in decades, Washington has been pushing governments around to world to squeeze out Huawei, arguing that the telecoms giant would transfer data to the Chinese government for espionage.

Huawei is one of the top customers for Sony’s image sensors for smartphones. Kioxia Holdings Corp is the world’s No. 2 maker of flash memory chips and a Huawei supplier.

Nikkei here said without U.S. licenses, Sony and Kioxia would face risk to their earnings.

Read More

Japan’s Sony and Kioxia seeking U.S. approval to supply to Huawei: Nikkei

FILE PHOTO: The Huawei logo is seen at the IFA consumer technology fair, amid the coronavirus disease (COVID-19) outbreak, in Berlin, Germany September 3, 2020. REUTERS/Michele Tantussi/File Photo

TOKYO (Reuters) – Japan’s Sony Corp and memory chipmaker Kioxia Holdings Corp have applied for U.S. approval to continue supplying Huawei Technologies Co Ltd, Nikkei reported on Sunday.

If confirmed, the move follows other tech companies such as Intel Corp that recently received licences from U.S. authorities.

With U.S.-China ties at their worst in decades, Washington has been pushing governments around to world to squeeze out Huawei, arguing that the telecoms giant would transfer data to the Chinese government for espionage.

Huawei is one of the top customers for Sony’s image sensors for smartphones. Kioxia Holdings Corp is the world’s No. 2 maker of flash memory chips and a Huawei supplier.

Nikkei here said without U.S. licenses, Sony and Kioxia would face

Read More

Google’s $2.1 billion Fitbit deal set for EU approval: Reuters

  • Google is expected to win EU approval for its $2.1 billion Fitbit deal after it addressed competition and data concerns, Reuters reported.
  • The internet giant has promised it will not use Fitbit data to personalize adverts for 10 years, according to a Financial Times report.
  • It will also ensure competitors can use its Android and Cloud platforms, according to people familiar with the matter.
  • The EU opened a four-month long investigation into Google’s acquisition of Fitbit in August. The deal was first announced in November 2019.
  • Visit Business Insider’s homepage for more stories.

Google’s $2.1 billion acquisition of wearables company Fitbit appears to have cleared a major hurdle.

It will be cleared by EU antitrust regulators after the tech giant agreed Tuesday to restrict how it uses customer data, according to multiple reports.

Google promised regulators that it would not personalize adverts based on user data for 10 years, up

Read More

Google’s $2.1 billion Fitbit takeover is set for regulator approval after the tech giant made new concessions on user data, according to reports



a close up of a sign: Google first announced the Fitbit acquisition in November 2019. Reuters


© Reuters
Google first announced the Fitbit acquisition in November 2019. Reuters

  • Google is expected to win EU approval for its $2.1 billion Fitbit deal after it addressed competition and data concerns, Reuters reported.
  • The internet giant has promised it will not use Fitbit data to personalize adverts for 10 years, according to a Financial Times report.
  • It will also ensure competitors can use its Android and Cloud platforms, according to people familiar with the matter.
  • The EU opened a four-month long investigation into Google’s acquisition of Fitbit in August. The deal was first announced in November 2019.
  • Visit Business Insider’s homepage for more stories.

Google’s $2.1 billion acquisition of wearables company Fitbit appears to have cleared a major hurdle.

Loading...

Load Error

It will be cleared by EU antitrust regulators after the tech giant agreed Tuesday to restrict how it uses customer data, according to multiple reports.

Google promised regulators

Read More

Analysts Reiterate Overweight Rating on Abbott Laboratories following European Approval of Freestyle Libre 3

On Monday, J.P. Morgan and Morgan Stanley reiterated their Overweight ratings on Abbott Laboratories (ABT). The company’s newest continuous glucose monitor (CGM), the Freestyle Libre 3, recently received a CE mark of approval. The system has shown to be a major evolutionary improvement over the current Libre 2 which leads analysts to believe that there are multiple long-term growth opportunities for Abbott.

The next-gen Libre CGM, Libre 3 will leverage Bluetooth technology to have continuous, real-time glucose readings automatically delivered to your smartphone every-minute (vs user scanning required in the past) allowing for unsurpassed 14-day accuracy and a ~70% size reduction from the Libre 1 & 2, becoming the world’s smallest and thinnest sensor.

The FreeStyle Libre 3 system was designed to fit perfectly into people’s everyday lives, allowing users to check their glucose as often as they like by just looking on their phones. This innovation allows the users

Read More

Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using its DehydraTECH technology in Delivering Antiviral Drugs

(TheNewswire)

Company Raises Commitment to Antiviral Research with Launch of Rodent Antiviral Drug Delivery Study with Potential COVID-19 Applications

Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today provides an update on a previously announced antiviral research initiative and introduces a new research project with potential COVID-19 applications

On March 19 2020, Lexaria announced that it planned to conduct a pilot human pharmacokinetic exploratory study in healthy volunteers of antiviral drugs that have previously been studied against other coronavirus strains, comparing Lexaria’s DehydraTECH TM formulations to controls without Lexaria’s technology.

The ethics board approval required as a first step in this pilot study has now been received, conditional on further government regulatory approval also being granted. Lexaria will now begin the process of pursuing the necessary steps to file for approval from federal regulators.

In parallel with this, Lexaria is also announcing

Read More

Adelman Travel Unveils Innovation in the Future of Pre-trip Approval

Hot Spot Approvals is a self-service, web-based solution focused on real-time employee safety

MILWAUKEE, Sept. 29, 2020 /PRNewswire/ — Corporate clients of Adelman Travel, with travel originating from the U.S., now have access to Hot Spot Approvals, a proprietary pre-trip approval technology designed to help them identify domestic and international high-risk locations and automatically approve or deny travel bookings based on a company’s requirements.

“Due to the global pandemic, travel protocols and requirements are changing constantly, and companies need to be able to evaluate risks and trigger approval requirements in real-time based on the destinations they choose,” said Steve Cline, President and COO of Adelman Travel. “Inclusive of our return to travel strategy and consultation with our customers, understanding their duty of care program and priorities, we are able to incorporate a solution that empowers them to keep their travelers safe and mitigate risks.”

Simple and Effective
Hot

Read More

Smartphone App For Diagnosing Autism Could Win FDA Approval

A system that uses A.I. to identify people with autism spectrum disorder (ASD) has been submitted to the U.S. Food and Drug Administration (FDA), and could become a valuable tool for primary care pediatricians in diagnosing autism. Its creators hope that it will help children with autism to be identified younger, thereby getting them the assistance they need sooner.

“Based on parent or pediatrician concern, a pediatrician would prescribe Cognoa’s parent-facing mobile application,” Dave Happel, CEO of Cognoa, told Digital Trends. “Once in the app, the parent answers a 10- to 15-minute questionnaire about their child’s behavioral patterns, then uploads two home videos of the child capturing their behavior in a natural environment. The videos are sent to a trained professional, who observes [them] and answers questions about their observations, which is fed into Cognoa’s algorithms. In addition, the pediatrician answers a questionnaire about the child’s behavior.”

Cognoa’s algorithm then

Read More